Composition for improving vascular endothelial function

Through a specific ratio of docosahexaenoic acid and sesamin composition, the problem of degradation of vascular endothelial function is solved, the vascular endothelial function is significantly improved, diseases such as arteriosclerosis are prevented or improved, and it is highly safe and easy Form of taking.

CN119095499APending Publication Date: 2024-12-06SUNTORY HLDG LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202380036129.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-05-16
Filing Date
2023-05-12
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art is difficult to effectively improve vascular endothelial function, leading to the occurrence of diseases such as arteriosclerosis, and traditional methods have shortcomings in the ease and safety of taking.

Method used

The use of docosahexaenoic acid compounds and sesamin compounds in combination by specific ratios forms a composition with improved vascular endothelial function for improving vascular endothelial function, specifically the weight of the sesamin compound and 20 The weight of the dicohexaenoic acid compound is set to a ratio of 2 to 150 and is used in oral or food.

Benefits of technology

It significantly increases the amount of nitric oxide production in vascular endothelial cells, reduces the reactive oxygen species in the cell, improves the vascular endothelial function, and prevents or improves related diseases such as arteriosclerosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005100034370000141
    Figure BDA0005100034370000141
  • Figure HDA0005100034380000011
    Figure HDA0005100034380000011
  • Figure HDA0005100034380000012
    Figure HDA0005100034380000012
Patent Text Reader

Abstract

The present invention addresses the problem of providing a composition for improving vascular endothelial function, which has an excellent vascular endothelial function improving effect. The present invention relates to a composition for improving vascular endothelial function, characterized by containing a sesamin-based compound and a docosahexaenoic acid compound, the docosahexaenoic acid compound being at least one compound selected from the group consisting of docosahexaenoic acid, a compound in which docosahexaenoic acid is included in constituent fatty acids, and salts of the docosahexaenoic acid, the docosahexaenoic acid and the docosahexaenoic acid. The weight of the sesamin compound in terms of sesamin is 2-150 relative to 100 of the weight of the docosahexaenoic acid compound in terms of docosahexaenoic acid.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a composition for improving vascular endothelial function, etc. Background Art

[0002] Endothelial cells are cells that make up the inner surface of blood vessels. Endothelial cells have the function of producing physiologically active substances such as nitric oxide (hereinafter sometimes simply referred to as NO), and play an important role in maintaining the health of blood vessels. The state of continuous decline in endothelial cell function (endothelial function) is related to the development of arteriosclerosis, etc. Since the decline in endothelial function is reversible, improving or preventing the decline in endothelial function is effective in preventing arteriosclerosis, etc.

[0003] Sesamin is one of the main lignan compounds contained in sesame. Non-Patent Document 1 states that sesamin can induce the production of nitric oxide in human umbilical vein endothelial cells (hereinafter sometimes referred to as HUVEC).

[0004] Docosahexaenoic acid (hereinafter sometimes simply referred to as DHA) is a type of highly unsaturated fatty acid contained in fish oil, etc. Non-patent document 2 describes that DHA increases NO production in HUVEC.

[0005] Non-patent literature Non-patent document 1: Lee, CC et al. J. Hypertens. 22, 2329-2338 (2004). Non-patent document 2: Jung, SB et al. Biochem. Biophys. Res. Commun. 437, 114-119 (2013). Summary of the invention

[0006] In order to improve endothelial function, it is necessary to continuously ingest the active ingredient. From the perspective of ease of administration and safety during continuous ingestion, a composition that can improve endothelial function even in a small amount is desired.

[0007] An object of the present invention is to provide a composition for improving vascular endothelial function having an excellent vascular endothelial function-improving effect.

[0008] The present inventors have conducted intensive studies to solve the above problems and have found that an excellent effect of improving vascular endothelial function can be obtained by using a docosahexaenoic acid compound and a sesamin compound in combination at a specific ratio.

[0009] The present invention includes the following compositions for improving vascular endothelial function, but is not limited thereto. [1] A composition for improving vascular endothelial function, characterized in that it contains a sesamin-like compound and a docosahexaenoic acid compound, wherein the docosahexaenoic acid compound is at least one compound selected from docosahexaenoic acid, compounds containing docosahexaenoic acid in constituent fatty acids, and salts thereof, and the weight of the sesamin-like compound in terms of sesamin is 2 to 150 parts per 100 parts by weight of the docosahexaenoic acid-converted compound. [2] The composition according to [1] above, wherein the weight of the sesamin-class compound in terms of sesamin is 2 to 110 per 100 of the weight of the docosahexaenoic acid-class compound in terms of docosahexaenoic acid. [3] The composition according to [1] or [2] above, wherein the sesamin-based compound is at least one compound selected from the group consisting of sesamin, episesamin, and metabolites thereof. [4] The composition according to any one of [1] to [3] above, characterized in that the compound containing docosahexaenoic acid as a constituent fatty acid is at least one compound selected from the group consisting of triglycerides whose fatty acids are partially or entirely docosahexaenoic acid, diglycerides whose fatty acids are partially or entirely docosahexaenoic acid, monoglycerides whose fatty acids are partially or entirely docosahexaenoic acid, phospholipids whose fatty acids are partially or entirely docosahexaenoic acid, glycolipids whose fatty acids are partially or entirely docosahexaenoic acid, and alcohol esters of docosahexaenoic acid. [5] The composition according to any one of [1] to [4] above, which is a composition for oral administration. [6] The composition according to any one of [1] to [5] above, which is a food or beverage. [7] The composition according to any one of [1] to [6] above, characterized in that it is labeled with at least one function selected from the group consisting of "improving endothelial function", "preventing a decrease in endothelial function", "protecting blood vessel health", "maintaining vascular flexibility", "dilating blood vessels to maintain blood flow", "promoting blood circulation", "improving blood flow to maintain body temperature", "improving blood flow to prevent or improve cold symptoms", "improving blood flow to prevent or improve shoulder stiffness", "preventing or improving edema", and "improving blood flow to improve skin condition". [8] An application of a composition containing a sesamin-like compound and a docosahexaenoic acid compound for improving vascular endothelial function, characterized in that the docosahexaenoic acid compound is at least one compound selected from docosahexaenoic acid, compounds containing docosahexaenoic acid in constituent fatty acids, and salts thereof, and in the composition, the weight of the sesamin-like compound in terms of sesamin is 2 to 150 parts per 100 parts by weight of the docosahexaenoic acid compound in terms of docosahexaenoic acid.

[0010] According to the present invention, a composition for improving vascular endothelial function having an excellent vascular endothelial function-improving effect can be provided. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 This is a graph showing the results of examining the amount of intracellular reactive oxygen species in human umbilical vein endothelial cells (HUVEC) by changing the weight ratio of docosahexaenoic acid (DHA) and sesamin metabolite (SC1) (mean ± standard error, N = 6). Figure 2 This is a graph showing the effect of the combination of DHA and SC1 on NO production in HUVEC (mean±standard error, N=5, Dunnett's test, *p<0.05, **p<0.01). DETAILED DESCRIPTION

[0012] The composition for improving vascular endothelial function of the present invention contains a sesamin-like compound and a docosahexaenoic acid compound, wherein the docosahexaenoic acid compound is at least one compound selected from docosahexaenoic acid, a compound containing docosahexaenoic acid in a constituent fatty acid, and a salt thereof, and the weight of the sesamin-like compound converted to sesamin is 2 to 150 relative to 100 of the weight of the docosahexaenoic acid-converted docosahexaenoic acid. Hereinafter, the composition for improving vascular endothelial function of the present invention may be simply referred to as the composition of the present invention. The composition of the present invention generally contains a sesamin-class compound and a docosahexaenoic acid-class compound as active ingredients.

[0013] In the present invention, the so-called sesamin compounds are a general term for compounds including sesamin and its structural analogs. Sesamin is a kind of main lignan compound contained in sesame. As structural analogs of sesamin, in addition to episesamin, for example, dioxabicyclo [3.3.0] octane derivatives recorded in Japanese Patent Publication No. 4-9331 can be cited. In the present invention, as sesamin compounds, one compound can be used alone, or two or more compounds can be used. As specific examples of sesamin compounds, exemplified are: sesamin, episesamin, sesamol, episesamol, sesamol, sesamolin, their metabolites, etc. Their stereoisomers or racemic forms can be used alone, or in combination. Metabolites that can be used as sesamin compounds include, for example, compounds described in Japanese Patent Application Laid-Open No. 2009-143884. Preferred metabolites of sesamin are SC1 ((7α, 7'α, 8α, 8'α)-3', 4'-methylenedioxy-7, 9': 7', 9-diepoxylignane-3, 4-diol) and SC2 ((7α, 7'α, 8α, 8'α)-7, 9': 7', 9-diepoxylignane-3, 3', 4, 4'-tetraol). Preferred metabolites are metabolites of sesamin, and more preferably SC1.

[0014] In the present invention, the sesamin-based compound is preferably at least one compound selected from sesamin, episesamin, and metabolites thereof. The metabolites of sesamin or episesamin are preferably SC1 and SC2, and more preferably SC1. In one embodiment, the sesamin-based compound is further preferably at least one compound selected from sesamin, episesamin, and SC1.

[0015] Sesamin compounds used in the present invention are not subject to any restrictions such as their form or manufacturing method. For example, in the case of sesamin, sesamin (also known as sesamin extract or refined product) extracted from sesame oil by a known method (for example, recorded in Japanese Patent Laid-Open No. 4-9331 Gazette) can be used. In addition, commercially available sesame oil (liquid) can also be used directly. However, when using sesame oil, because sometimes evaluating the unique flavor of sesame oil is not preferred on the sense organ, therefore, it is preferred to use the tasteless and odorless sesamin extract (or sesamin refined product) extracted from sesame oil. In addition, when using sesame oil, because the sesamin content is low, if you want to allocate the sesamin of the ideal amount, the volume of each unit of the composition of the formula will become too large, so sometimes inconvenience will be generated in the intake. Especially for oral intake, when the preparation is made, the preparation (tablet, capsule, etc.) will become too large and cause the intake to produce obstacles. Therefore, from the perspective of the small amount of intake, it is also preferred to use the sesamin extract (or sesamin refined product) extracted from sesame oil. Sesamin can also be obtained by synthesis. As a method thereof, for example, sesamin and episesamin can be synthesized by the method of Beroza et al. (J. Am. Chem. Soc., 78, 1242 (1956)). Sesamin compounds can also be produced by the method described in, for example, Japanese Patent Application Laid-Open No. 2009-143884.

[0016] In the present invention, as the docosahexaenoic acid compound, at least one selected from docosahexaenoic acid (free docosahexaenoic acid), a compound containing docosahexaenoic acid in a constituent fatty acid, and a salt thereof is used. As the docosahexaenoic acid compound, one compound may be used alone, or two or more compounds may be used. The compound containing docosahexaenoic acid in a constituent fatty acid may be hydrolyzed to separate docosahexaenoic acid.

[0017] Examples of the salt of docosahexaenoic acid or a compound containing docosahexaenoic acid in a constituent fatty acid include calcium salts and sodium salts. As the compound containing docosahexaenoic acid as a constituent fatty acid, it is preferable to be at least one compound selected from the group consisting of triglycerides in which a part or all of the fatty acids are docosahexaenoic acid, diglycerides in which a part or all of the fatty acids are docosahexaenoic acid, monoglycerides in which a part or all of the fatty acids are docosahexaenoic acid, phospholipids in which a part or all of the fatty acids are docosahexaenoic acid, glycolipids in which a part or all of the fatty acids are docosahexaenoic acid, and alcohol esters of docosahexaenoic acid. Among them, as the docosahexaenoic acid compound, docosahexaenoic acid, triglycerides in which a part or all of the fatty acids are docosahexaenoic acid, diglycerides in which a part or all of the fatty acids are docosahexaenoic acid, and phospholipids in which a part or all of the fatty acids are docosahexaenoic acid are more preferred; docosahexaenoic acid, triglycerides in which a part or all of the fatty acids are docosahexaenoic acid, and diglycerides in which a part or all of the fatty acids are docosahexaenoic acid are further preferred; docosahexaenoic acid and triglycerides in which a part or all of the fatty acids are docosahexaenoic acid are particularly preferred.

[0018] The docosahexaenoic acid compounds used in the present invention are not subject to any restrictions such as their form or production method, and chemically synthesized products can be used, and substances derived from natural products or substances derived from genetically modified organisms (Escherichia coli, yeast, plants, etc.) can also be used. As substances derived from natural products, seafood, algae, fungi (Colwellia bacteria, Coccinella, etc.), and plants (liverworts, etc.) rich in docosahexaenoic acid compounds can be listed. Among them, docosahexaenoic acid compounds are preferably derived from seafood. In addition, docosahexaenoic acid compounds extracted and / or purified from raw materials such as natural products containing docosahexaenoic acid compounds can also be used, and the raw materials can also be used directly to make the composition contain docosahexaenoic acid compounds. As the raw material containing docosahexaenoic acid compounds, for example, edible oils and fats such as oils extracted from fish oil, meat, and milk can be listed. As the fish oil containing docosahexaenoic acid compounds, it is preferred to concentrate the fish oil in a manner such that the content of docosahexaenoic acid compounds (converted in docosahexaenoic acid) reaches 5% by weight or more, preferably 10% by weight or more, and more preferably 50% by weight or more. For example, docosahexaenoic acid compounds extracted and / or purified from fish oil containing docosahexaenoic acid compounds can be used, and the fish oil can also be used directly.

[0019] In the composition of the present invention, the weight of the sesamin-class compound in terms of sesamin is 2 to 150 parts per 100 parts by weight of the docosahexaenoic acid-class compound in terms of docosahexaenoic acid. By using the docosahexaenoic acid compound and the sesamin compound in the above weight ratio, an excellent vascular endothelial function improvement effect can be obtained. In the present invention, with respect to the weight ratio of the docosahexaenoic acid compound and the sesamin compound, the weight of the sesamin compound converted to sesamin is 2 or more, preferably 2.5 or more, more preferably 3 or more, and further preferably 3.1 or more, relative to the weight of the docosahexaenoic acid compound converted to docosahexaenoic acid 100, and is 150 or less, preferably 110 or less, more preferably 109 or less, and further preferably 108 or less. In one embodiment of the present invention, the weight of the sesamin compound converted to sesamin is preferably 2 to 110, more preferably 2.5 to 110, further preferably 3 to 109, and particularly preferably 3.1 to 108, relative to the weight of the docosahexaenoic acid compound converted to docosahexaenoic acid 100. When the weight ratio of the docosahexaenoic acid compound to the sesamin compound is within the above range, a more excellent vascular endothelial function-improving effect can be obtained.

[0020] In the present invention, the amount of a sesamin-like compound, when two or more compounds are used as a sesamin-like compound, refers to their total amount. The amount of a sesamin-like compound converted to sesamin or an expression similar thereto, when sesamin is used as a sesamin-like compound, refers to its amount. When a compound other than sesamin is used as a sesamin-like compound, it refers to the value obtained by multiplying the number of moles of the compound by the molecular weight of sesamin.

[0021] In the present invention, the amount of docosahexaenoic acid compounds refers to their total amount when two or more compounds are used as docosahexaenoic acid compounds. The amount of docosahexaenoic acid compounds converted to docosahexaenoic acid or similar expressions refer to the amount thereof when docosahexaenoic acid is used as a docosahexaenoic acid compound. In the case where the docosahexaenoic acid compound is not free docosahexaenoic acid, it is converted in the form of free docosahexaenoic acid. In the case where the docosahexaenoic acid compound is not free docosahexaenoic acid, docosahexaenoic acid can be freed by saponification or enzyme treatment, and the docosahexaenoic acid can be measured to obtain the amount converted to docosahexaenoic acid.

[0022] Endothelial function refers to the role of endothelial cells. The role of endothelial cells plays an important role in maintaining vascular health, including the production of nitric oxide (NO) by endothelial cells. Nitric oxide is one of the endothelial-derived relaxing factors and is produced in vivo by nitric oxide synthase (NOS). In the present invention, improvement of vascular endothelial function or expressions similar thereto include inhibition of decline of vascular endothelial function, maintenance of vascular endothelial function, and restoration of decreased vascular endothelial function.

[0023] As shown in the examples described below, by using docosahexaenoic acid compounds and sesamin compounds in combination in a manner where the weight of the docosahexaenoic acid compound (converted in terms of docosahexaenoic acid) is 2 to 150 relative to the weight of the docosahexaenoic acid compound (converted in terms of docosahexaenoic acid) of 100, the amount of intracellular reactive oxygen species can be effectively reduced in vascular endothelial cells compared to the case where these compounds are not used. That is, in vascular endothelial cells, the oxidative stress in the cells can be effectively reduced. In vascular endothelial cells, if the amount of intracellular reactive oxygen species increases, the amount of NO produced decreases. In vascular endothelial cells, NO production can be promoted by reducing intracellular reactive oxygen species. In vascular endothelial cells, endothelial function can be improved by reducing intracellular reactive oxygen species. Therefore, by using docosahexaenoic acid compounds and sesamin compounds in combination at the above weight ratio, endothelial function can be effectively improved. As shown in the Examples, when docosahexaenoic acid compounds and sesamin compounds are used in combination at the above weight ratio, the relative NO production of HUVECs is significantly increased compared to the control group. On the other hand, in HUVECs cultured with only docosahexaenoic acid compounds or sesamin compounds added, no significant increase in relative NO production was confirmed compared to the control group. It has not been reported so far that an excellent vascular endothelial function improvement effect can be obtained by using docosahexaenoic acid compounds and sesamin compounds in combination at the above weight ratio. In one aspect, the composition of the present invention can be used to improve endothelial function by reducing intracellular reactive oxygen species in endothelial cells.

[0024] In one embodiment, the improvement of endothelial function can be to promote the production of NO in endothelial cells. In one embodiment, the composition of the present invention can be used to promote the production of nitric oxide in endothelial cells. When the production of NO in endothelial cells increases, blood vessels dilate, which can increase blood flow (promote blood circulation). Therefore, by promoting the production of nitric oxide in endothelial cells, blood flow can be improved.

[0025] In one embodiment, the composition of the present invention can be used to dilate blood vessels and increase blood flow due to the improvement of endothelial function. In addition, the health (functionality) of blood vessels can be maintained by the improvement of endothelial function, thereby maintaining the softness and elasticity of blood vessels. Therefore, the composition of the present invention is useful, for example, in maintaining or improving the softness and elasticity of blood vessels. In one embodiment, the composition of the present invention can be used to maintain or improve the softness and / or elasticity of blood vessels.

[0026] The composition for improving vascular endothelial function of the present invention can be used to prevent or improve conditions or diseases that can be expected to be prevented or improved by improving vascular endothelial function. Examples of such conditions or diseases include arteriosclerosis and conditions or diseases caused by decreased blood flow. In this specification, prevention of a condition or disease includes preventing the onset of a condition or disease, delaying the onset of a condition or disease, reducing the incidence of a condition or disease, alleviating the risk of onset of a condition or disease, etc. Improvement of a condition or disease includes recovering the subject from the condition or disease, improving the symptoms of the condition or disease, alleviating the symptoms of the condition or disease, delaying or preventing the development of the condition or disease, etc. Recovery also includes partial recovery.

[0027] Sesamin compounds and docosahexaenoic acid compounds are contained in natural products or food and beverages and are compounds with edible experience. Therefore, from the perspective of safety, it is generally believed that sesamin compounds and docosahexaenoic acid compounds have fewer problems, such as daily intake. According to the present invention, a composition containing a highly safe substance as an effective ingredient and having an excellent vascular endothelial function improvement effect can be provided.

[0028] The composition for improving vascular endothelial function of the present invention can be used for either therapeutic purposes (medical purposes) or non-therapeutic purposes (non-medical purposes). The term "non-therapeutic" refers to a concept that does not include medical actions, that is, human surgery, treatment or diagnosis. The composition for improving endothelial function of the present invention can be made into the form of food, cosmetics, pharmaceuticals, quasi-drugs, feeds, etc. The composition of the present invention itself can be a food, cosmetics, pharmaceuticals, quasi-drugs, feeds, etc. for improving endothelial function, or it can be a raw material or preparation used by being deployed in these. The composition for improving endothelial function of the present invention can be provided in the form of a drug, as an example, but is not limited to this form. The drug can be directly used as a composition, or provided in the form of a composition containing the drug. In one embodiment, the composition of the present invention can also be referred to as a endothelial function improving agent.

[0029] The composition of the present invention can be any of an oral composition and a non-oral composition. In one embodiment, the composition of the present invention is preferably an oral composition. As an oral composition, food and drink, oral pharmaceuticals, quasi-pharmaceuticals, and feeds can be listed, preferably food and drink or oral pharmaceuticals, more preferably food and drink.

[0030] As long as the effect of the present invention is not impaired, the composition of the present invention may further contain any additives or any ingredients on the basis of the sesamin compounds and the docosahexaenoic acid compounds. These additives and ingredients may be selected according to the form of the composition, and substances generally applicable to food and beverage, cosmetics, pharmaceuticals, quasi-drugs, feeds, etc. may be used. When the composition of the present invention is made into food and beverage, cosmetics, pharmaceuticals, quasi-drugs, feeds, etc., its manufacturing method is not particularly limited and may be manufactured by a general method.

[0031] For example, when the composition of the present invention is made into food and drink, the ingredients (for example, food raw materials, food additives used as needed, etc.) that can be used for food and drink can be prepared in sesame compounds and docosahexaenoic acid compounds, and various food and drink can be made. Food and drink are not particularly limited, and for example, general food and drink, health food, health drink, functional labeled food, specific health food, health supplement food, patient food and drink, etc. can be listed. The above-mentioned health food, functional labeled food, specific health food, health supplement food, etc., for example, can be used in various preparation forms such as granules, tablets, granules, powders, capsules, chewables, dry syrups, syrups, liquids, beverages, drinks, liquid foods, etc.

[0032] When the composition of the present invention is made into cosmetics, various cosmetics can be prepared by mixing ingredients that can be used in cosmetics (such as carriers and additives allowed in cosmetics) with sesamin compounds and docosahexaenoic acid compounds. The product form of the cosmetics is not particularly limited, and examples thereof include skin care cosmetics such as lotions, beauty serums, facial masks, emulsions, creams, and sunscreens.

[0033] When the composition of the present invention is made into a pharmaceutical or quasi-drug, for example, a pharmacologically acceptable carrier, an additive added as needed, etc. can be prepared into pharmaceuticals or quasi-drugs in various dosage forms in sesamin compounds and docosahexaenoic acid compounds. Such carriers, additives, etc. can be used as long as they are pharmacologically acceptable substances for pharmaceuticals or quasi-drugs, for example, one or more of excipients, binders, disintegrants, lubricants, antioxidants, colorants, etc. can be listed. As the dosage form of pharmaceuticals or quasi-drugs, oral or non-oral (dermal, mucosal, enteral, injection, etc.) dosage forms can be listed. In one embodiment, when the composition of the present invention is made into a pharmaceutical or quasi-drug, it is preferably made into a pharmaceutical or quasi-drug for oral use. As the dosage form for oral administration, liquid, tablet, powder, fine granule, granule, sugar-coated tablet, capsule, suspension, emulsion, chewable tablet, etc. can be listed. Pharmaceuticals can be medicines for non-human animals.

[0034] When the composition of the present invention is made into feed, the sesamin-based compounds and docosahexaenoic acid-based compounds can be mixed into the feed. Feed also includes feed additives. Examples of feed include: livestock feed for cattle, pigs, chickens, sheep, horses, etc.; feed for small animals such as rabbits, rats, mice, etc.; pet food for dogs, cats, birds, etc., etc.

[0035] The content of the sesamin-like compounds contained in the composition of the present invention is not particularly limited and can be set according to its form, etc. The content of the sesamin-like compounds in the composition of the present invention is preferably 0.01% by weight or more, more preferably 0.1% by weight or more, further preferably 0.3% by weight or more, and further preferably 50% by weight or less, calculated on a sesamin basis. In one embodiment, the content of the sesamin-like compounds is preferably 0.01 to 50% by weight, more preferably 0.1 to 50% by weight, and further preferably 0.3 to 50% by weight in the composition, calculated on a sesamin basis. The content of sesamin-class compounds can be measured by high performance liquid chromatography (HPLC). When two or more sesamin-class compounds are contained, the amount of sesamin-class compounds refers to the total amount of these compounds.

[0036] The content of the docosahexaenoic acid compound contained in the composition of the present invention is not particularly limited and can be set according to its form, etc. The content of the docosahexaenoic acid compound in the composition of the present invention is preferably 0.3% by weight or more, more preferably 5% by weight or more, further preferably 10% by weight or more, particularly preferably 20% by weight or more, and preferably 80% by weight or less, calculated on a docosahexaenoic acid basis. In one embodiment, the content of the docosahexaenoic acid compound is preferably 0.3 to 80% by weight, more preferably 5 to 80% by weight, further preferably 10 to 80% by weight, and particularly preferably 20 to 80% by weight in the composition, calculated on a docosahexaenoic acid basis. The content of docosahexaenoic acid can be measured by gas chromatography (GC).

[0037] The composition of the present invention can be taken or administered by various methods known per se according to its form or dosage form. In one embodiment, the composition of the present invention is preferably taken orally (administered orally). The dosage (also called intake) of the composition of the present invention is not particularly limited. The dosage of the composition of the present invention can be any amount that can improve vascular endothelial function, and can be appropriately set according to the dosage form, dosage method, and subject weight.

[0038] In one embodiment, when a human (adult) is used as a subject to ingest or administer the composition of the present invention, the dosage of the sesamin compound is preferably 0.1 mg or more per day, more preferably 1 mg or more, and further preferably 3 mg or more, and preferably 500 mg or less, in terms of sesamin conversion. In one embodiment, the dosage of the sesamin compound is preferably 0.1 to 500 mg per day, more preferably 1 to 500 mg, and further preferably 3 to 500 mg per day in the case of a human (adult). The above dosage can be the dosage per 60 kg of body weight or per day.

[0039] When a person (adult) is taken as an object and the composition of the present invention is taken or administered, the dosage of the docosahexaenoic acid compound is preferably 3 mg or more per day, more preferably 50 mg or more, further preferably 100 mg or more, particularly preferably 200 mg or more, and preferably 800 mg or less, calculated as docosahexaenoic acid. In one embodiment, the dosage of the docosahexaenoic acid compound (calculated as docosahexaenoic acid) is preferably 3 to 800 mg per day in the case of a person (adult), more preferably 50 to 800 mg, further preferably 100 to 800 mg, and particularly preferably 200 to 800 mg. The above dosage can be the dosage per 60 kg of body weight and per day. The above amount of sesamin compounds and docosahexaenoic acid is preferably taken or administered once a day or divided into several times (e.g., 2-3 times). In one embodiment, the above amount of sesamin compounds and docosahexaenoic acid is preferably taken or administered orally. In one embodiment, the composition for improving vascular endothelial function of the present invention can be used to allow a person to ingest or administer the above-mentioned amount of sesamin-based compounds and docosahexaenoic acid-based compounds per 60 kg of body weight per day.

[0040] The composition of the present invention is preferably a substance that can be continuously ingested or administered. By continuously ingesting or administering a sesamin compound and a docosahexaenoic acid compound, a better effect of improving vascular endothelial function can be expected. In one embodiment, the composition of the present invention is preferably continuously ingested or administered for more than 1 week, more preferably more than 4 weeks, further preferably more than 8 weeks, and particularly preferably more than 12 weeks.

[0041] The subject to which the composition of the present invention is ingested or administered (also referred to as the administration subject) is not particularly limited, but is preferably a human or a non-human mammal, and more preferably a human. In one embodiment, as the subject of administration, there can be cited subjects who need or wish to improve endothelial function. It is known that endothelial function decreases with age, so as such subjects, for example, middle-aged and elderly people can be cited. In one embodiment, the composition of the present invention can be suitable for use as a composition for improving endothelial function for middle-aged and elderly people. Middle-aged and elderly people include the elderly. For example, the middle-aged and elderly people can be people over 40 years old. In one embodiment, among the middle-aged and elderly people, the elderly are preferably used as the subject. For example, the elderly can be people over 60 years old or over 65 years old. The subject of administration can also be a healthy person. The composition of the present invention can also be used for a healthy person for the purpose of preventing or improving a state or disease that can be expected to be prevented or improved due to the improvement of endothelial function.

[0042] The composition for improving vascular endothelial function of the present invention may be provided with a label indicating a function of improving or preventing a decline in vascular function or a decline in vascular endothelial function. The composition for improving vascular endothelial function of the present invention may be provided with a label indicating at least one function selected from the group consisting of "improving vascular endothelial function", "preventing a decline in vascular endothelial function", "protecting the health of blood vessels", "maintaining the flexibility of blood vessels", "dilatating blood vessels to maintain blood flow", "promoting blood circulation", "improving blood flow to maintain body temperature", "improving blood flow to prevent or improve cold symptoms", "improving blood flow to prevent or improve shoulder stiffness", "preventing or improving edema", and "improving blood flow to improve skin condition". In one embodiment of the present invention, the composition of the present invention is preferably a food and beverage product with the above-mentioned indication. In addition, the above-mentioned indication can be an indication for obtaining the above-mentioned function. The above-mentioned indication can be attached to the composition itself, or to a container or a package of the composition.

[0043] The present invention also includes the following methods. A method for improving vascular endothelial function, comprising administering a composition containing a sesamin-like compound and a docosahexaenoic acid compound to a subject, wherein the docosahexaenoic acid compound is at least one compound selected from docosahexaenoic acid, a compound containing docosahexaenoic acid in a constituent fatty acid, and a salt thereof, and wherein the weight of the sesamin-like compound in the composition is 2 to 150 parts by weight in terms of docosahexaenoic acid relative to 100 parts by weight of the docosahexaenoic acid compound. The above methods may be therapeutic methods or non-therapeutic methods. By administering the above composition to a subject, vascular endothelial function can be improved.

[0044] The present invention also includes the following applications. An application is the application of a composition containing sesamin compounds and docosahexaenoic acid compounds for improving vascular endothelial function, wherein the docosahexaenoic acid compound is at least one compound selected from docosahexaenoic acid, compounds containing docosahexaenoic acid in constituent fatty acids, and salts thereof, and in the composition, the weight of the sesamin compounds converted to sesamin is 2 to 150 relative to 100 of the weight of the docosahexaenoic acid compound converted to docosahexaenoic acid. The above application is preferably directed to humans or non-human mammals, more preferably to humans. The application may be a therapeutic application or a non-therapeutic application.

[0045] In the above methods and applications, sesamin compounds, docosahexaenoic acid compounds and preferred embodiments thereof are the same as those of the composition for improving vascular endothelial function of the present invention. The preferred embodiment of the weight ratio of docosahexaenoic acid compounds and sesamin compounds is also the same as that of the composition for improving vascular endothelial function of the present invention. As sesamin compounds, one type of sesamin compounds may be used alone, or two or more types may be used. As docosahexaenoic acid compounds, one type of docosahexaenoic acid compounds may be used alone, or two or more types may be used. In the above methods and applications, the composition is preferably administered to the subject (made to ingest) more than once a day, for example, once to several times a day (for example, 2 to 3 times). In one embodiment, in the above methods and applications, the composition is preferably administered (ingested) orally.

[0046] In the above methods and applications, it is sufficient to use the amount of sesamin compounds and docosahexaenoic acid compounds (also called effective amount) that can achieve the desired effect. The preferred dosage or subject of sesamin compounds and docosahexaenoic acid compounds is the same as that of the above composition of the present invention. In one embodiment, the above composition can be used to prevent or improve the state or disease such as arteriosclerosis. In one embodiment, the above composition can be used to prevent or improve the decline of vascular endothelial function with aging.

[0047] The present invention also includes an application of a sesamin compound and a docosahexaenoic acid compound for manufacturing a composition for improving vascular endothelial function. The docosahexaenoic acid compound is a compound selected from at least one of docosahexaenoic acid, compounds containing docosahexaenoic acid in constituent fatty acids, and their salts. In the above-mentioned composition, the sesamin compound and the docosahexaenoic acid compound are preferably used in a manner that the weight of the sesamin compound converted to sesamin reaches 2 to 150 relative to 100 of the weight of the docosahexaenoic acid compound converted to docosahexaenoic acid. The composition for improving vascular endothelial function and its preferred embodiment are the same as described above.

[0048] In this specification, the numerical range represented by the lower limit and the upper limit, i.e., "lower limit - upper limit", includes these lower limit and upper limit. For example, the range represented by "1 to 2" means 1 or more and 2 or less, and includes 1 and 2. In this specification, the upper limit and the lower limit can be set as a range of any combination. Example

[0049] The present invention will be described in more detail below based on examples. However, the present invention is not limited to these examples.

[0050] <Example 1> 1-1. Test methods In order to investigate whether the combination of docosahexaenoic acid and sesaminoids has an effect on vascular function, human umbilical vein endothelial cells (HUVEC) were used to explore its usefulness. As the docosahexaenoic acid compound, docosahexaenoic acid (DHA) was used. DHA (Sigma-Aldrich) was dissolved in dimethyl sulfoxide (DMSO) (Nacalai Tesque Co., Ltd.). Since sesamin is metabolized in the body, SC1, a major metabolite detected in human blood after sesamin ingestion, was used in this experiment. SC1 was dissolved in DMSO.

[0051] HUVEC (LONZA Co., Ltd.) was seeded in a 96-well plate, thawed using EGM-2 (LONZA Co., Ltd.), and cultured in a CO2 incubator (37°C, 5% CO2, ambient O2, humidified). On the second day after seeding in the 96-well plate, the culture medium (EGM-2) was replaced with DMSO or the test substance (DHA and SC1), and cultured in a CO2 incubator for 24 hours. Cells cultured in the culture medium supplemented with DMSO were used as a control group.

[0052] Table 1 shows the concentrations of the test substances (DHA and SC1) in the culture medium and the weight ratio of DHA to SC1. The weight ratio of DHA to SC1 is expressed as the weight ratio of SC1 when the weight of DHA is set to 100. The weight ratio of SC1 converted to sesamin (SE) when the weight of DHA is set to 100 is shown in parentheses.

[0053] [Table 1]

[0054] Then, the culture medium was replaced with CellROX Deep Red (Thermo Fisher) and Hoechst 33342 (Thermo Fisher). After incubation in a CO2 incubator for 30 minutes, the fluorescence intensity of CellROX Deep Red (excitation wavelength 635nm, detection wavelength 675nm) and the fluorescence intensity of Hoechst 33342 (excitation wavelength 350nm, detection wavelength 460nm) were measured using a plate reader. The fluorescence intensity of CellROX Deep Red was corrected with the fluorescence intensity of Hoechst334, and the relative fluorescence intensity was used as the relative intracellular oxidative stress level. The greater the relative fluorescence intensity, the greater the amount of reactive oxygen species in the cell.

[0055] 1-2. Results The results are as follows Figure 1 shown. Figure 1 This is a graph showing the results of examining the amount of intracellular reactive oxygen species in human umbilical vein endothelial cells (HUVEC) by changing the weight ratio of docosahexaenoic acid (DHA) and sesamin metabolite (SC1) (mean ± standard error, N = 6). Figure 1 The results shown are expressed as relative values ​​when the amount of intracellular reactive oxygen species in the control group (DMSO) was set to 1. Figure 1 1 to 6 in represent ratios 1 to 6 in Table 1, respectively. By combining DHA and sesamin metabolites, the amount of reactive oxygen species in vascular endothelial cells decreased for ratios 3, 4, and 5. On the other hand, no change in the amount of reactive oxygen species in cells was observed for ratios 1, 2, and 6. The above shows that by combining DHA and sesamin metabolites at a weight ratio of ratio 3, ratio 4, or ratio 5, the amount of reactive oxygen species in cells in vascular endothelial cells can be effectively reduced.

[0056] From the above results, it can be seen that if docosahexaenoic acid compounds and sesamins are used in combination in the form of 2 to 150 weights of sesamins converted to sesamin relative to 100 weights of docosahexaenoic acid compounds converted to docosahexaenoic acid, it is possible to effectively increase the production of NO in vascular endothelial cells. SC1 is a metabolite of sesamin. In addition, if a compound containing DHA in the constituent fatty acids is ingested, the compound will be hydrolyzed in the body to generate docosahexaenoic acid. Therefore, for sesamins other than SC1 such as sesamin and docosahexaenoic acid compounds other than DHA, by ingesting them in combination at the above weight ratio, the same effect as when using DHA and SC1 can be obtained.

[0057] <Example 2> 2-1. Test methods HUVECs were cultured in the same manner as in Example 1. On the second day after seeding in a 96-well plate, the cells were cultured in a CO2 incubator for 24 hours in a medium (EGM-2) supplemented with the test substance or a positive control group. DHA and SC1 were used as the test substances. In addition, lovastatin (Fujifilm Wako Pure Chemical Industries, Ltd.), which is known to increase NO production, was used as a positive control group. The test substances were added to the culture medium in such a manner that DHA became 1 μM and SC1 became 1 μM (the weight of SC1 was 104.2 (107.9 in terms of sesamin conversion) relative to the weight of DHA of 100). Lovastatin was added in such a manner that the concentration in the culture medium became 10 μM. Cells cultured in a culture medium supplemented with DMSO were used as a control group. In addition, a culture medium (DHA: 1 μM) supplemented with only DHA instead of the test substances (DHA and SC1) and a culture medium (SC1: 1 μM) supplemented with only SC1 were prepared, and HUVECs were cultured in the same manner as above. DHA, SC1 and lovastatin were dissolved in DMSO and then added to the culture medium.

[0058] Then, the culture medium was replaced with DAF-2 (4,5-diaminofluorescein, Goryo Chemical Co., Ltd.) added at a final concentration of 10 μM. After incubation in a CO2 incubator for 2 hours, the culture supernatant was transferred to a 96-well black plate and the fluorescence intensity (ex. 485 nm, em. 515 nm) was measured using an ELISA reader (N = 5). A cell-free culture medium was used as the background, and the same measurement was performed. The average value of the background was subtracted from the fluorescence intensity of each sample (N = 5), and the relative fluorescence intensity was used as the relative NO production.

[0059] 2-2. Results The results are as follows Figure 2 shown. Figure 2 This is a graph showing the effect of the combination of DHA and sesamin metabolite (SC1) on NO production in HUVEC (mean ± standard error, N = 5, Dunnett's test, *p < 0.05, **p < 0.01). Figure 2The results shown are expressed as the relative values ​​of the relative NO production of cells cultured in the medium with the test substance (or positive control) added when the relative NO production of the control group (DMSO 0.1v / v%) is set to 1. The NO production is significantly increased compared with the control group by the combination of DHA and sesamin metabolites. On the other hand, no significant increase in the relative NO production was confirmed for HUVEC cultured with only DHA or SC1 added relative to the control group. By combining docosahexaenoic acid compounds and sesamin compounds, NO production in vascular endothelial cells can be effectively increased, thereby improving vascular endothelial function.

Claims

1. A composition for improving vascular endothelial function, characterized in that Contains sesamin compounds and docosahexaenoic acid compounds. The docosahexaenoic acid compound is at least one compound selected from the group consisting of docosahexaenoic acid, compounds containing docosahexaenoic acid in constituent fatty acids, and salts thereof. The weight of the sesamin-class compound in terms of sesamin is 2 to 150 parts per 100 parts of the docosahexaenoic acid-class compound in terms of docosahexaenoic acid.

2. The composition according to claim 1, characterized in that The weight of the sesamin-class compound in terms of sesamin is 2 to 110 relative to 100 of the weight of the docosahexaenoic acid-class compound in terms of docosahexaenoic acid.

3. The composition according to claim 1 or 2, characterized in that The sesamin-based compound is at least one compound selected from the group consisting of sesamin, episesamin, and metabolites thereof.

4. The composition according to claim 1 or 2, characterized in that The compound containing docosahexaenoic acid in its constituent fatty acids is at least one compound selected from triglycerides whose constituent fatty acids are partly or entirely docosahexaenoic acid, diglycerides whose constituent fatty acids are partly or entirely docosahexaenoic acid, monoglycerides whose constituent fatty acids are partly or entirely docosahexaenoic acid, phospholipids whose constituent fatty acids are partly or entirely docosahexaenoic acid, glycolipids whose constituent fatty acids are partly or entirely docosahexaenoic acid, and alcohol esters of docosahexaenoic acid.

5. The composition according to claim 1 or 2, characterized in that It is a composition for oral administration.

6. The composition according to claim 1 or 2, characterized in that It is a food and drink.

7. The composition according to claim 1 or 2, characterized in that An indication of at least one function selected from the group consisting of "improving endothelial function", "preventing a decline in endothelial function", "protecting blood vessel health", "maintaining vascular flexibility", "dilating blood vessels to maintain blood flow", "promoting blood circulation", "improving blood flow to maintain body temperature", "improving blood flow to prevent or improve cold symptoms", "improving blood flow to prevent or improve shoulder pain", "preventing or improving edema" and "improving blood flow to improve skin condition".

8. An application of a composition containing a sesamin-like compound and a docosahexaenoic acid-like compound for improving vascular endothelial function, characterized in that: The docosahexaenoic acid compound is at least one compound selected from docosahexaenoic acid, compounds containing docosahexaenoic acid in constituent fatty acids, and salts thereof. In the composition, the weight of the docosahexaenoic acid compound converted to docosahexaenoic acid is 2 to 150, relative to 100 of the weight of the docosahexaenoic acid compound converted to docosahexaenoic acid.

Citation Information

Patent Citations

  • Hepatic function improver

    JP1992009331A

  • Method for producing dioxabicyclo[3. 3. 0]octane derivative having catechol group introduced thereto

    JP2009143884A